Snowflake Score | |
---|---|
Valuation | 1/6 |
Future Growth | 0/6 |
Past Performance | 0/6 |
Financial Health | 5/6 |
Dividends | 0/6 |
A085660 Stock Overview
CHA Biotech Co., Ltd., together with its subsidiaries, engages in cell therapy development, cord blood, and stem cell banking services.
CHA Biotech Competitors
Price History & Performance
Historical stock prices | |
---|---|
Current Share Price | ₩17,400.00 |
52 Week High | ₩31,100.00 |
52 Week Low | ₩15,500.00 |
Beta | 1.03 |
1 Month Change | -6.45% |
3 Month Change | 4.82% |
1 Year Change | -9.14% |
3 Year Change | 6.75% |
5 Year Change | 39.76% |
Change since IPO | 133.13% |
Recent News & Updates
Is CHA Biotech (KOSDAQ:085660) Using Too Much Debt?
The external fund manager backed by Berkshire Hathaway's Charlie Munger, Li Lu, makes no bones about it when he says...
If You Had Bought CHA Biotech's (KOSDAQ:085660) Shares Three Years Ago You Would Be Down 52%
CHA Biotech Co., Ltd. ( KOSDAQ:085660 ) shareholders should be happy to see the share price up 19% in the last quarter...
Shareholder Returns
A085660 | KR Healthcare | KR Market | |
---|---|---|---|
7D | 0% | 7.5% | 1.6% |
1Y | -9.1% | -39.9% | -14.2% |
Return vs Industry: A085660 exceeded the KR Healthcare industry which returned -39.9% over the past year.
Return vs Market: A085660 exceeded the KR Market which returned -14.2% over the past year.
Price Volatility
A085660 volatility | |
---|---|
A085660 Average Weekly Movement | 4.5% |
Healthcare Industry Average Movement | 5.8% |
Market Average Movement | 5.5% |
10% most volatile stocks in KR Market | 10.4% |
10% least volatile stocks in KR Market | 3.2% |
Stable Share Price: A085660 is not significantly more volatile than the rest of KR stocks over the past 3 months, typically moving +/- 4% a week.
Volatility Over Time: A085660's weekly volatility (4%) has been stable over the past year.
About the Company
Founded | Employees | CEO | Website |
---|---|---|---|
2002 | 205 | n/a | https://www.chabio.com |
CHA Biotech Co., Ltd., together with its subsidiaries, engages in cell therapy development, cord blood, and stem cell banking services. The company operates a cord blood consignment storage business for the treatment of intractable diseases, as well as provides regenerative medicines, Immune and stem cell storage services, anti-aging, and solutions for incurable diseases; medical wellness programs comprising fitness, spa, and supplements; and customized development, production, clinical, and commercialization services to customers with research and development, and clinical experience. It also offers optimized IT system construction and operation; consulting services for development, operation, and expansion of Chaum model; and solutions for maternal-centered genome testing and personalized healthcare.
CHA Biotech Fundamentals Summary
A085660 fundamental statistics | |
---|---|
Market Cap | ₩979.07b |
Earnings (TTM) | -₩21.37b |
Revenue (TTM) | ₩747.67b |
1.3x
P/S Ratio-45.8x
P/E RatioIs A085660 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
A085660 income statement (TTM) | |
---|---|
Revenue | ₩747.67b |
Cost of Revenue | ₩534.15b |
Gross Profit | ₩213.51b |
Other Expenses | ₩234.88b |
Earnings | -₩21.37b |
Last Reported Earnings
Mar 31, 2022
Next Earnings Date
n/a
Earnings per share (EPS) | -379.72 |
Gross Margin | 28.56% |
Net Profit Margin | -2.86% |
Debt/Equity Ratio | 41.6% |
How did A085660 perform over the long term?
See historical performance and comparisonValuation
Is CHA Biotech undervalued compared to its fair value and its price relative to the market?
Valuation Score
1/6Valuation Score 1/6
Below Fair Value
Significantly Below Fair Value
PE vs Industry
PE vs Market
PEG Ratio
PB vs Industry
2.11x
Price to Book (PB) ratio
Share Price vs. Fair Value
Below Fair Value: Insufficient data to calculate A085660's fair value for valuation analysis.
Significantly Below Fair Value: Insufficient data to calculate A085660's fair value for valuation analysis.
Price To Earnings Ratio
PE vs Industry: A085660 is unprofitable, so we can't compare its PE Ratio to the Asian Healthcare industry average.
PE vs Market: A085660 is unprofitable, so we can't compare its PE Ratio to the KR market.
Price to Earnings Growth Ratio
PEG Ratio: Insufficient data to calculate A085660's PEG Ratio to determine if it is good value.
Price to Book Ratio
PB vs Industry: A085660 is good value based on its PB Ratio (2.1x) compared to the KR Healthcare industry average (2.3x).
Future Growth
How is CHA Biotech forecast to perform in the next 1 to 3 years based on estimates from 0 analysts?
Future Growth Score
0/6Future Growth Score 0/6
Earnings vs Savings Rate
Earnings vs Market
High Growth Earnings
Revenue vs Market
High Growth Revenue
Future ROE
16.6%
Forecasted Healthcare industry annual growth in earnings
In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as CHA Biotech has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.
This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.
Past Performance
How has CHA Biotech performed over the past 5 years?
Past Performance Score
0/6Past Performance Score 0/6
Quality Earnings
Growing Profit Margin
Earnings Trend
Accelerating Growth
Earnings vs Industry
High ROE
-4.3%
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: A085660 is currently unprofitable.
Growing Profit Margin: A085660 is currently unprofitable.
Past Earnings Growth Analysis
Earnings Trend: A085660 is unprofitable, and losses have increased over the past 5 years at a rate of 4.3% per year.
Accelerating Growth: Unable to compare A085660's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: A085660 is unprofitable, making it difficult to compare its past year earnings growth to the Healthcare industry (33.2%).
Return on Equity
High ROE: A085660 has a negative Return on Equity (-4.21%), as it is currently unprofitable.
Financial Health
How is CHA Biotech's financial position?
Financial Health Score
5/6Financial Health Score 5/6
Short Term Liabilities
Long Term Liabilities
Debt Level
Reducing Debt
Stable Cash Runway
Forecast Cash Runway
Financial Position Analysis
Short Term Liabilities: A085660's short term assets (₩577.5B) exceed its short term liabilities (₩414.7B).
Long Term Liabilities: A085660's short term assets (₩577.5B) exceed its long term liabilities (₩354.3B).
Debt to Equity History and Analysis
Debt Level: A085660 has more cash than its total debt.
Reducing Debt: A085660's debt to equity ratio has increased from 27.5% to 41.6% over the past 5 years.
Balance Sheet
Cash Runway Analysis
For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: A085660 has sufficient cash runway for more than 3 years based on its current free cash flow.
Forecast Cash Runway: A085660 has sufficient cash runway for 2.4 years if free cash flow continues to reduce at historical rates of 37% each year.
Dividend
What is CHA Biotech current dividend yield, its reliability and sustainability?
Dividend Score
0/6Dividend Score 0/6
Notable Dividend
High Dividend
Stable Dividend
Growing Dividend
Earnings Coverage
Future Dividend Coverage
Dividend Yield vs Market
Notable Dividend: Unable to evaluate A085660's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate A085660's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if A085660's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if A085660's dividend payments have been increasing.
Earnings Payout to Shareholders
Earnings Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Cash Payout to Shareholders
Cash Flow Coverage: Unable to calculate sustainability of dividends as A085660 has not reported any payouts.
Discover strong dividend paying companies
Management
How experienced are the management team and are they aligned to shareholders interests?
CEO
CHA Biotech has no CEO, or we have no data on them.
Ownership
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Ownership Breakdown
Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 5.5%.
Top Shareholders
Company Information
CHA Biotech Co., Ltd.'s employee growth, exchange listings and data sources
Key Information
- Name: CHA Biotech Co., Ltd.
- Ticker: A085660
- Exchange: KOSDAQ
- Founded: 2002
- Industry: Health Care Facilities
- Sector: Healthcare
- Implied Market Cap: ₩979.069b
- Shares outstanding: 56.27m
- Website: https://www.chabio.com
Number of Employees
Location
- CHA Biotech Co., Ltd.
- CHA Bio Complex
- 335 Pangyoro
- Seongnam-si
- Gyeonggi-do
- South Korea
Listings
Company Analysis and Financial Data Status
Data | Last Updated (UTC time) |
---|---|
Company Analysis | 2022/05/22 00:00 |
End of Day Share Price | 2022/05/20 00:00 |
Earnings | 2022/03/31 |
Annual Earnings | 2021/12/31 |
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.